RxDoctor Payments DataLook up a doctor →

Mark Janicki, MD

Neurology · Lebanon, INNPI 1588661409

Payments from drug & device makers

$582,272in general payments, 2019–2025

Across 2,023 payments — averaging $287.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$253K
  • Sanofi$141K
  • Biogen$51K
  • AstraZeneca$36K
  • Vanda Pharmaceuticals Inc.$29K
  • Johnson & Johnson$16K
  • plus $56K from 54 others

What the payments were for

  • Consulting fees$38,2647%
  • Speaking & faculty fees$479,43884%
  • Travel & lodging$20,8194%
  • Food & beverage$34,0746%
  • Education$7540%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
EMD Serono, Inc.346$253,433
Sanofi195$140,597
Biogen72$50,559
AstraZeneca(2 entities)81$36,340
Vanda Pharmaceuticals Inc.37$28,546
Johnson & Johnson(2 entities)37$16,212
Bristol Myers Squibb37$12,946
Genentech USA, Inc.45$11,468
Novartis103$9,627
E.r. Squibb & Sons, L.L.C.7$4,372
AbbVie(2 entities)216$2,572
Amgen(2 entities)77$2,362
UCB, Inc.129$1,828
Janssen Scientific Affairs, LLC1$1,320
Teva Pharmaceuticals USA, Inc.61$966
Pfizer68$624
Lilly USA, LLC50$602
Neurocrine Biosciences, Inc.35$554
Argenx US, Inc.33$515
Impel Pharmaceuticals Inc.45$476
Banner Life Sciences, LLC21$451
Harmony Biosciences LLC12$406
Sunovion Pharmaceuticals Inc.29$334
Sumitomo Pharma America, Inc.14$311
Eisai Inc.17$297
Sanofi-aventis U.S. LLC8$296
MDD US Operations, LLC17$295
Lundbeck LLC12$272
Neurelis, Inc.22$260
SK Life Science, Inc.13$253
Acadia Pharmaceuticals Inc14$250
Avanir Pharmaceuticals, Inc.14$229
CSL Behring11$227
TG Therapeutics, Inc.3$223
Jazz Pharmaceuticals Inc.11$219
Biohaven Pharmaceuticals, Inc.14$165
Xeris Pharmaceuticals, Inc.9$151
Amneal Pharmaceuticals LLC9$142
Biohaven Pharmaceutical Holding Company Ltd.15$139
Upsher-smith Laboratories LLC6$124
Acorda Therapeutics, Inc8$116
Otsuka America Pharmaceutical, Inc.5$93
Azurity Pharmaceuticals, Inc.4$77
Cycle Pharmaceuticals Inc4$74
Adamas Pharmaceuticals, Inc.4$73
GRT US Holding, Inc.4$73
Supernus Pharmaceuticals, Inc.5$68
Takeda Pharmaceuticals U.S.A., Inc.3$59
Livanova USA, Inc.4$57
Mallinckrodt Hospital Products Inc.4$56
Genentech, Inc.3$56
Tanabe Pharma America, Inc.3$56
Scilex Pharmaceuticals Inc.3$54
Currax Pharmaceuticals LLC4$50
Axsome Therapeutics, Inc.3$48
Aprecia Pharmaceuticals, LLC3$47
Bausch Health US, LLC2$46
Arbor Pharmaceuticals, Inc.2$40
Aucta Pharmaceuticals, Inc.1$26
Almatica Pharma LLC1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$582,272 in reported general payments places this provider in the 95th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$59,985
Medicare patients
228
Services billed
1,336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate23$188,991
AubagioTeriflunomide13$118,987
Avonex Pen (4 Pack)Interferon Beta-1a14$109,841
NuplazidPimavanserin Tartrate20$100,318
AptiomEslicarbazepine Acetate39$75,172
AmpyraDalfampridine13$55,255
Emgality PenGalcanezumab-Gnlm19$23,714
Nurtec OdtRimegepant Sulfate17$17,587
UbrelvyUbrogepant12$16,942
Aimovig AutoinjectorErenumab-Aooe17$14,817
Dalfampridine ErDalfampridine18$7,430
Teriflunomide24$7,014
Pregabalin128$3,532
Carbamazepine ErCarbamazepine20$3,039
Donepezil Hcl162$2,370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$554$188,99123 claims
SanofiAubagio$140,597$118,98713 claims
Acadia Pharmaceuticals IncNuplazid$250$100,31820 claims
Sunovion Pharmaceuticals Inc.Aptiom$334$75,17239 claims
Acorda Therapeutics, IncAmpyra$116$55,25513 claims
PfizerNurtec Odt$624$17,58717 claims
AbbVieUbrelvy$2,572$16,94212 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$142$78312 claims
Upsher-smith Laboratories LLCTopiramate$124$31131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 neurology providers in Indiana.

Other neurology in Lebanon

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →